Role of prucalopride, a serotonin (5-HT4) receptor agonist, for the treatment of chronic constipation
Open Access
- 1 May 2010
- journal article
- review article
- Published by Taylor & Francis in Clinical and Experimental Gastroenterology
- Vol. 3, 49-56
Abstract
Role of prucalopride, a serotonin (5-HT4) receptor agonist, for the treatment of chronic constipation Banny S Wong, Noriaki Manabe, Michael CamilleriClinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic, Rochester, Minnesota, USA Constipation affects up to a quarter of the population in developed countries and is associated with poor quality of life and significant economic burden. Many patients with chronic constipation are dissatisfied with current therapy due to lack of long-term efficacy or side effects. Previous nonselective 5-hydroxytryptamine receptor 4 (5-HT4) agonists have been associated with significant interactions with other receptors (5-HT1B, 5-HT1D, and 5-HT2B for tegaserod; hERG for cisapride), leading to adverse cardiovascular events resulting in withdrawal of these drugs from the market. Prucalopride is a novel gastrointestinal prokinetic agent. It acts as a high affinity, highly-selective 5-HT4 agonist. Its efficacy in patients with chronic constipation has been demonstrated in several phase II and phase III clinical trials showing significant improvements in bowel transit, bowel function, gastrointestinal symptoms, and quality of life, with benefit maintained for up to 24 months in open label, multicenter, follow-up studies. Prucalopride’s high selectivity for the 5-HT4 receptor may explain its favorable safety and tolerability profiles, even in elderly subjects with stable cardiovascular disease. Prucalopride is a well tolerated and efficacious prokinetic medication that should enhance the treatment of chronic constipation unresponsive to first-line treatments.Keywords: prucalopride, 5-HT4 agonist, serotonin agonist, efficacy, prokineticKeywords
This publication has 64 references indexed in Scilit:
- Safety assessment of prucalopride in elderly patients with constipation: a double‐blind, placebo‐controlled studyNeurogastroenterology & Motility, 2009
- Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjectsAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2009
- Selective desensitization of the 5‐HT4receptor‐mediated response in pig atrium but not in stomachBritish Journal of Pharmacology, 2009
- Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12‐week, randomized, double‐blind, placebo‐controlled studyAlimentary Pharmacology & Therapeutics, 2008
- Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxativesGut, 2008
- Porcine left atrial and sinoatrial 5‐HT4receptor‐induced responses: fading of the response and influence of developmentBritish Journal of Pharmacology, 2006
- A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipationGut, 2005
- The Health-Related Quality of Life and Economic Burden of ConstipationPharmacoEconomics, 2005
- Prucalopride Is Effective in Patients with Severe Chronic Constipation in Whom Laxatives Fail to Provide Adequate ReliefDigestion, 2003
- Anorectal manometric abnormalities and colonic propulsive impairment in patients with severe chronic idiopathic constipationDigestive Diseases and Sciences, 1994